← Home
Wiki page

eatl

How to read this page

Start with the article narrative. Use the right sidebar to jump from prose into concept context, nearby graph relationships, and source provenance.

The most feared complication of celiac disease — a rare cancer of the intestinal T cells, strongly linked to uncontrolled inflammation and refractory disease.

Enteropathy-associated T-cell lymphoma (EATL) is an aggressive cancer of T lymphocytes arising in the small intestinal lining. It is the most common cancer complication of celiac disease, though it remains rare in absolute terms. Its association with celiac — particularly RCD type 2 — is one of the primary reasons strict GFD adherence and treatment of refractory disease are medically urgent.

Connection to Celiac Disease

EATL develops along a recognizable continuum:

Normal celiac disease on GFD
    → Untreated / poorly controlled celiac
    → Refractory celiac disease (RCD)
    → RCD Type 2 (aberrant IELs, clonal expansion)
    → EATL

The il-15-driven aberrant IEL population in RCD type 2 is considered a pre-malignant state — the clonally expanding IELs gradually accumulate genetic mutations and can transform into frank lymphoma.

Risk Factors

  • Older age at celiac diagnosis
  • RCD type 2 — highest risk group
  • Long history of uncontrolled/untreated celiac disease
  • Not being on a GFD

Strict long-term GFD adherence significantly reduces but does not eliminate EATL risk.

Presentation

EATL often presents with:

  • Abdominal pain, weight loss, diarrhea (overlapping with active celiac)
  • Ulceration, perforation of the small intestine
  • Constitutional symptoms: fever, night sweats
  • New deterioration after previous disease control

The overlap with celiac symptoms can cause diagnostic delays.

Prognosis

EATL carries a poor prognosis with low 5-year survival rates. It is aggressive and often diagnosed at advanced stage. Treatment involves intensive chemotherapy and sometimes autologous stem cell transplant.

Two Subtypes

Historical EATL has been reclassified (WHO 2016):

  • EATL (formerly Type 1) — strongly associated with celiac and HLA-DQ2/DQ8; accounts for most celiac-related cases
  • MEITL (Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, formerly Type 2) — less associated with celiac; different genetic profile

Monitoring

The rationale for the monitoring protocol in celiac — including regular follow-up, TTG IgA, and vigilance for symptoms — is partly to detect progression toward EATL early, particularly in patients with suspected RCD.

refractory-celiac | intraepithelial-lymphocytes | il-15 | gluten-free-diet | management | cytokines-celiac

Referenced In

symptoms | management | terminology | glossary | research_plan